Yu. Yu. Varlamova
Research Subjects
Yu. Yu. Varlamova has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Ю. Ю. Варламова
ГБУЗ ДКЦ № 1 ДЗМ
4 shared publications- A. I. Sapina
I.V. Davydovsky City Clinical Hospital, Moscow Healthcare Department
3 shared publications - Alexey S. Bezymyanniy
Directorate for coordination of activities of medical organizations of the Department of Health of the city of Moscow
3 shared publications - Elena Yu. Vasilieva
I.V. Davydovsky City Clinical Hospital; Russian University of Medicine
3 shared publications - M. G. Papyrina
City Clinic № 46
3 shared publications - Vera N. Larina
Pirogov Russian National Research Medical University
3 shared publications
Latest Publications
- Open Access
- 15 August 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (9S) , 6752
An integrated approach to a multimorbid patient with extreme risk of cardiovascular events. A case report
Introduction . Coronary artery disease (CAD) remains one of the leading causes of mortality and disability worldwide. Despite advances in cardiology, a significant proportion of patients with progressive coronary atherosclerosis require multiple surgical and endovascular interventions. Long-term mortality after percutaneous coronary intervention (PCI) remains high. Successful management of these patients requires not only the choice of interventional tactics but also effective secondary prevention, the key element of which is achieving target low-density lipoprotein cholesterol (LDL-C) levels. Brief description . A 73-year-old patient with a long-standing history of CAD, hypertension, multiple risk factors, and multiple episodes of stent restenosis and thrombosis after coronary artery bypass grafting and a series of PCIs in 2013-2018. Due to identified resistance to clopidogrel, antiplatelet therapy was escalated with ticagrelor, which enabled control of thrombotic events. Despite therapy with rosuvastatin 20 mg and ezetimibe 10 mg, LDL-C levels remained elevated (3,02 mmol/L), which did not meet the target value of Discussion . This case demonstrates not only the importance of identifying clopidogrel resistance in restenosis but also the efficacy of inclisiran as a long-term lipid management option in patients with CAD, dyslipidemia, and intolerance to high doses of statins.
- 15 August 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (9S) , 6752
Open AccessAn integrated approach to a multimorbid patient with extreme risk of cardiovascular events. A case report
Introduction . Coronary artery disease (CAD) remains one of the leading causes of mortality and disability worldwide. Despite advances in cardiology, a significant proportion of patients with progressive coronary atherosclerosis require multiple surgical and endovascular interventions. Long-term mortality after percutaneous coronary intervention (PCI) remains high. Successful management of these patients requires not only the choice of interventional tactics but also effective secondary prevention, the key element of which is achieving target low-density lipoprotein cholesterol (LDL-C) levels. Brief description . A 73-year-old patient with a long-standing history of CAD, hypertension, multiple risk factors, and multiple episodes of stent restenosis and thrombosis after coronary artery bypass grafting and a series of PCIs in 2013-2018. Due to identified resistance to clopidogrel, antiplatelet therapy was escalated with ticagrelor, which enabled control of thrombotic events. Despite therapy with rosuvastatin 20 mg and ezetimibe 10 mg, LDL-C levels remained elevated (3,02 mmol/L), which did not meet the target value of Discussion . This case demonstrates not only the importance of identifying clopidogrel resistance in restenosis but also the efficacy of inclisiran as a long-term lipid management option in patients with CAD, dyslipidemia, and intolerance to high doses of statins.
- Open Access
- 3 May 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (5S) , 6224
Biventricular hypertrophic cardiomyopathy with ACTC1 and LDB3 mutations, results of primary prevention of sudden cardiac death: а case report
Introduction. Hypertrophic cardiomyopathy (HCM) significantly increases the risk of sudden cardiac death (SCD), especially in young patients. Familial HCM requires an individual approach to risk stratification and determining indications for primary prevention of SCD.Brief description. This case describes a patient with a rare genetic anomaly (a combination of ACTC1 and LDB3 mutations). Thanks to timely diagnosis, indications for a cardioverter-defibrillator implantation were determined, which made it possible to stop an episode of ventricular fibrillation (VF). The case describes the changes of the patient's echocardiographic parameters, morphological features (biventricular myocardial hypertrophy, myocardial bridge), as well as the disease course, therapeutic approaches and 6-year treatment outcomes.Discussion. Careful stratification of SCD risk, including assessment of family history, constant monitoring with dynamic echocardiography and Holter monitoring, allowed timely implantation of a cardioverter-defibrillator and stopping VF. Preventive measures, continuity between the inpatient and outpatient stages saved the patient's life, improved the prognosis and slowed the progression of left ventricular hypertrophy. A rare genetic variant of HCM with mutations in the ACTC1 and LDB3 genes has been described in only three cases over 5 years, which emphasizes the scientific significance of this case. The combination of biventricular hypertrophy, myocardial bridge, and episodes of ventricular tachycardia and VF may be associated with this genotype, which requires further study to improve SCD risk management strategies.
- 3 May 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (5S) , 6224
Open AccessBiventricular hypertrophic cardiomyopathy with ACTC1 and LDB3 mutations, results of primary prevention of sudden cardiac death: а case report
Introduction. Hypertrophic cardiomyopathy (HCM) significantly increases the risk of sudden cardiac death (SCD), especially in young patients. Familial HCM requires an individual approach to risk stratification and determining indications for primary prevention of SCD.Brief description. This case describes a patient with a rare genetic anomaly (a combination of ACTC1 and LDB3 mutations). Thanks to timely diagnosis, indications for a cardioverter-defibrillator implantation were determined, which made it possible to stop an episode of ventricular fibrillation (VF). The case describes the changes of the patient's echocardiographic parameters, morphological features (biventricular myocardial hypertrophy, myocardial bridge), as well as the disease course, therapeutic approaches and 6-year treatment outcomes.Discussion. Careful stratification of SCD risk, including assessment of family history, constant monitoring with dynamic echocardiography and Holter monitoring, allowed timely implantation of a cardioverter-defibrillator and stopping VF. Preventive measures, continuity between the inpatient and outpatient stages saved the patient's life, improved the prognosis and slowed the progression of left ventricular hypertrophy. A rare genetic variant of HCM with mutations in the ACTC1 and LDB3 genes has been described in only three cases over 5 years, which emphasizes the scientific significance of this case. The combination of biventricular hypertrophy, myocardial bridge, and episodes of ventricular tachycardia and VF may be associated with this genotype, which requires further study to improve SCD risk management strategies.
- Open Access
- 2 December 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (12) , 6177
Evaluation of lipoprotein(a) — a novel cardiovascular risk factor in patients with atherosclerotic cardiovascular diseases receiving PCSK9-targeted therapy in Russian real-world practice
Aim. To evaluate the effect of PCSK9-targeted therapy on lipoprotein(a) (Lp(a)) levels in patients with atherosclerotic cardiovascular diseases who have not achieved the target low-density lipoprotein cholesterol (LDL-C) level (statins at maximum tolerated doses and/or ezetimibe).Material and methods. The study involved 3 Moscow medical facilities of the state healthcare system. The study included 50 people who received inclisiran therapy, 30 people — PCSK9 inhibitors (alirocumab, n=1; evolocumab, n=29). This analysis presents the results of Lp(a) level changes over 12-month inclisiran therapy. Lp(a) was determined by turbidimetry. Elevated Lp(a) level was defined as ≥50 mg/dL (125 nmol/L).Results. Normal Lp(a) levels were determined in 16 subjects (34,8%), moderate — in 9 subjects (19,6%), high — in 21 subjects (45,7%), and extremely high (>180 mg/dL) — in 8 subjects (17,4%). Inclisiran therapy was associated with a significant (pConclusion. Lp(a) assessment may be appropriate with ongoing PSCK9-targeted therapy. Diagnosis of hyper-Lp(a) is important for early intensive combination lipid-lowering therapy and modification of risk factors in order to reduce the risk of cardiovascular diseases.
- 2 December 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (12) , 6177
Open AccessEvaluation of lipoprotein(a) — a novel cardiovascular risk factor in patients with atherosclerotic cardiovascular diseases receiving PCSK9-targeted therapy in Russian real-world practice
Aim. To evaluate the effect of PCSK9-targeted therapy on lipoprotein(a) (Lp(a)) levels in patients with atherosclerotic cardiovascular diseases who have not achieved the target low-density lipoprotein cholesterol (LDL-C) level (statins at maximum tolerated doses and/or ezetimibe).Material and methods. The study involved 3 Moscow medical facilities of the state healthcare system. The study included 50 people who received inclisiran therapy, 30 people — PCSK9 inhibitors (alirocumab, n=1; evolocumab, n=29). This analysis presents the results of Lp(a) level changes over 12-month inclisiran therapy. Lp(a) was determined by turbidimetry. Elevated Lp(a) level was defined as ≥50 mg/dL (125 nmol/L).Results. Normal Lp(a) levels were determined in 16 subjects (34,8%), moderate — in 9 subjects (19,6%), high — in 21 subjects (45,7%), and extremely high (>180 mg/dL) — in 8 subjects (17,4%). Inclisiran therapy was associated with a significant (pConclusion. Lp(a) assessment may be appropriate with ongoing PSCK9-targeted therapy. Diagnosis of hyper-Lp(a) is important for early intensive combination lipid-lowering therapy and modification of risk factors in order to reduce the risk of cardiovascular diseases.
- Open Access
- 25 May 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (6) , 5943
Effectiveness of inclisiran lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Moscow healthcare
Aim. To evaluate the effectiveness of PCSK9-targeted therapy (inclisiran, alirocumab, and evolocumab) in patients with atherosclerotic cardiovascular disease (ASCVD) and who did not achieve the target low-density lipoprotein cholesterol (LDL-C) level on basic therapy (statins in maximum tolerated doses and/or ezetimibe). Material and methods. This observational study included 50 patients receiving the inclisiran and 30 patients of the control group with ASCVD treated with PCSK9 inhibitors (alirocumab, n=1; evolocumab, n=29). In all participants, we assessed medical history data and initially performed electrocardiography, echocardiography, Doppler ultrasound of extracranial and lower limb arteries, and laboratory tests (complete blood count, biochemical and lipid profile). Three Moscow public health facilities took part in the study. Results. Data on achievement of primary and secondary endpoints by the 12 th month are presented. The study groups were comparable in basic clinical characteristics. In inclisiran group, a significant decrease in LDL-C level was found from 2,53±0,7 mmol/l initially to 1,29±0,5 mmol/l (by 49%), p=0,0002; the target LDL-C Conclusion. The final results are consistent with the intermediate data and indicate not only the possibility of early achievement of target LDL-C levels in PCSK9targeted combination therapy, but their maintenance with a favorable tolerability and safety profile.
- 25 May 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (6) , 5943
Open AccessEffectiveness of inclisiran lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Moscow healthcare
Aim. To evaluate the effectiveness of PCSK9-targeted therapy (inclisiran, alirocumab, and evolocumab) in patients with atherosclerotic cardiovascular disease (ASCVD) and who did not achieve the target low-density lipoprotein cholesterol (LDL-C) level on basic therapy (statins in maximum tolerated doses and/or ezetimibe). Material and methods. This observational study included 50 patients receiving the inclisiran and 30 patients of the control group with ASCVD treated with PCSK9 inhibitors (alirocumab, n=1; evolocumab, n=29). In all participants, we assessed medical history data and initially performed electrocardiography, echocardiography, Doppler ultrasound of extracranial and lower limb arteries, and laboratory tests (complete blood count, biochemical and lipid profile). Three Moscow public health facilities took part in the study. Results. Data on achievement of primary and secondary endpoints by the 12 th month are presented. The study groups were comparable in basic clinical characteristics. In inclisiran group, a significant decrease in LDL-C level was found from 2,53±0,7 mmol/l initially to 1,29±0,5 mmol/l (by 49%), p=0,0002; the target LDL-C Conclusion. The final results are consistent with the intermediate data and indicate not only the possibility of early achievement of target LDL-C levels in PCSK9targeted combination therapy, but their maintenance with a favorable tolerability and safety profile.
- Open Access
- 20 December 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 28 (12) , 5687
Observational study of inclisiran effectiveness in Moscow healthcare
Aim. To evaluate the effectiveness of PCSK9 inhibitors (alirocumab, inclisiran and evolocumab) in patients with atherosclerotic cardiovascular disease (ASCVD) and failure to achieve the target low-density lipoprotein cholesterol (LDL-C) level for the period from November 21, 2022 to December 31, 2023.Material and methods. For the observational study, 50 patients were included in the inclisiran therapy group and 30 patients in the control group (patients with ASCVD receiving PCSK9 inhibitors (alirocumab, n=1; evolocumab, n=29)). All study participants had their anamnestic data analyzed, and initially underwent electrocardiography, echocardiography, extracranial and lower limb Doppler ultrasound, and laboratory tests (complete blood count, biochemical blood tests, lipid profile). Three medical organizations of the Moscow State Healthcare System participate in the study.Results. Interim data are presented to evaluate the effectiveness of PCSK9 targeted therapy in patients with ASCVD, obtained 3 months from the study start. The comparison groups were comparable in main clinical characteristics. When analyzing the lipid-lowering effect of inclisiran in the examined patients with ASCVD, LDL-C level significantly decreased from 2,53±0,10 mmol/l to 110±0,08 mmol/l (by 56,5%), pConclusion. The use of PCSK9 targeted therapy (alirocumab or inclisiran or evolocumab) in patients with ASCVD in Moscow make it possible to achieve target LDL-C levels, which are indicated in clinical guidelines, by 3 months.
- 20 December 2023
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 28 (12) , 5687
Open AccessObservational study of inclisiran effectiveness in Moscow healthcare
Aim. To evaluate the effectiveness of PCSK9 inhibitors (alirocumab, inclisiran and evolocumab) in patients with atherosclerotic cardiovascular disease (ASCVD) and failure to achieve the target low-density lipoprotein cholesterol (LDL-C) level for the period from November 21, 2022 to December 31, 2023.Material and methods. For the observational study, 50 patients were included in the inclisiran therapy group and 30 patients in the control group (patients with ASCVD receiving PCSK9 inhibitors (alirocumab, n=1; evolocumab, n=29)). All study participants had their anamnestic data analyzed, and initially underwent electrocardiography, echocardiography, extracranial and lower limb Doppler ultrasound, and laboratory tests (complete blood count, biochemical blood tests, lipid profile). Three medical organizations of the Moscow State Healthcare System participate in the study.Results. Interim data are presented to evaluate the effectiveness of PCSK9 targeted therapy in patients with ASCVD, obtained 3 months from the study start. The comparison groups were comparable in main clinical characteristics. When analyzing the lipid-lowering effect of inclisiran in the examined patients with ASCVD, LDL-C level significantly decreased from 2,53±0,10 mmol/l to 110±0,08 mmol/l (by 56,5%), pConclusion. The use of PCSK9 targeted therapy (alirocumab or inclisiran or evolocumab) in patients with ASCVD in Moscow make it possible to achieve target LDL-C levels, which are indicated in clinical guidelines, by 3 months.
- Open Access
- 1 May 2023
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 63 (4) , 11-15
Current approaches to the treatment of patients with dyslipidemia in the real practice in the outpatient stage
Aim To evaluate the frequency and structure of lipid-lowering therapy and of achieving the goal of low-density lipoprotein cholesterol (LDL-C) in patients with very high cardiovascular risk (CVR) who were monitored at the outpatient stage. Material and methods A retrospective snapshot analysis was performed by continuous sampling method for 136 medical records of outpatient patients (71 men, 65 women) aged 42 to 91 years [median, 68 years; 25th and 75th percentiles (59; 78)]. Results 134 (98,53 %) patients took statins; 8 (5.88 %) patients took a combination of statin and ezetimibe; 2 (1.47 %) patients took proprotein convertase subtilisin/kexin type 9 enzyme inhibitors (PCSK9): 2 (1.47 %) patients took evolocumab and 1 (0.74%) of 2 PCSK9-treated patients took a combination of PCSK9 inhibitor and statin. Atorvastatin at a dose of 20 (20; 40) mg as recommended at the hospital was the most frequently prescribed statin. 5 (3.68%) patients achieved the goal LDL-C of ≤1.4 mmol/l. Conclusion Statins prevail in the structure of lipid-lowering therapy in patients with very high CVR. The frequency of combination therapy (statin/ezetimibe, 5.88%; PCSK9 inhibitor/statin, 0.74%) and PCSK9 inhibitors was noted to be low. Only 3.68% of patients achieved the goal LDL-C during the lipid-lowering treatment.
- 1 May 2023
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 63 (4) , 11-15
Open AccessCurrent approaches to the treatment of patients with dyslipidemia in the real practice in the outpatient stage
Aim To evaluate the frequency and structure of lipid-lowering therapy and of achieving the goal of low-density lipoprotein cholesterol (LDL-C) in patients with very high cardiovascular risk (CVR) who were monitored at the outpatient stage. Material and methods A retrospective snapshot analysis was performed by continuous sampling method for 136 medical records of outpatient patients (71 men, 65 women) aged 42 to 91 years [median, 68 years; 25th and 75th percentiles (59; 78)]. Results 134 (98,53 %) patients took statins; 8 (5.88 %) patients took a combination of statin and ezetimibe; 2 (1.47 %) patients took proprotein convertase subtilisin/kexin type 9 enzyme inhibitors (PCSK9): 2 (1.47 %) patients took evolocumab and 1 (0.74%) of 2 PCSK9-treated patients took a combination of PCSK9 inhibitor and statin. Atorvastatin at a dose of 20 (20; 40) mg as recommended at the hospital was the most frequently prescribed statin. 5 (3.68%) patients achieved the goal LDL-C of ≤1.4 mmol/l. Conclusion Statins prevail in the structure of lipid-lowering therapy in patients with very high CVR. The frequency of combination therapy (statin/ezetimibe, 5.88%; PCSK9 inhibitor/statin, 0.74%) and PCSK9 inhibitors was noted to be low. Only 3.68% of patients achieved the goal LDL-C during the lipid-lowering treatment.